You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA258
  • Published:  27 June 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): comments on the ACD received from the public through the NICE website
10 May 2012
(44.27 Kb 12 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 08 May 2012

Back to top